The value of information service for the rational use of nootropics in preferential drug provision

Abstract

The rational prescription of medicines with preferential drugs provision, including nootropics, which are widely used in patients receiving pharmacotherapy under the «Program for Providing Certain Categories of Citizens with Necessary Drugs», is possible only if modern evidence is available.Aim. Conduct information content of the «Database of Clinical Trials of Medicines» for relevant in preferential drugs provision: cerebrolysin there is no international non-proprietary name; piracetam; livestock cortex polypeptides; citicoline and create recommendations on the use of nootropics.Materials and methods. Search and analysis of the results of clinical trials, systematic Reviews and meta-analysis was carried out in the international databases PubMed, EMBASE, Cochrane Collaboration, followed by entering into the electronic resource «Database of Clinical Trials of Medicines» for nootropics.Results. Nootropics have a positive effect mainly on the studied «surrogate» outcomes (improving the clinical condition of patients), without significantly affecting clinical outcomes (reducing the number of adverse outcomes and mortality) in severe neurological pathology.Conclusion.Service «Database of Clinical Trials of Drugs» for use by healthcare professionals and recommendations on the use of nootropics can apply for rational drugs prescription in preferential drugs provision.